Efficacy of flash glucose monitoring on HbA1c in type 2 diabetes: An individual patient data meta-analysis of real-world evidence

IF 6.1 3区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes research and clinical practice Pub Date : 2025-01-01 DOI:10.1016/j.diabres.2024.111950

Randeep S. Heer, Joshua Lovegrove, Zoë Welsh

{"title":"Efficacy of flash glucose monitoring on HbA1c in type 2 diabetes: An individual patient data meta-analysis of real-world evidence","authors":"Randeep S. Heer, Joshua Lovegrove, Zoë Welsh","doi":"10.1016/j.diabres.2024.111950","DOIUrl":null,"url":null,"abstract":"<div><h3>Aims</h3><div>There is a growing body of evidence demonstrating the benefit of flash glucose monitoring in type 2 diabetes mellitus (T2DM). This individual patient data <em>meta</em>-analysis aimed to investigate the impact of commencing flash glucose monitoring on HbA1c in people living with T2DM treated with insulin in a real-world setting.</div></div><div><h3>Methods</h3><div>A <em>meta</em>-analysis of eight observational studies which assessed change in HbA1c at 3–6 months following initiating flash glucose monitoring for which Abbott Diabetes Care could provide individual patient data was performed. Studies included adults with T2DM managed with insulin and baseline HbA1c between 8.0 %–12.0 % (64–108 mmol/mol). A one-stage model was created to explore heterogeneity.</div></div><div><h3>Results</h3><div>A total of 803 patients were included in the analysis (mean(SD) age: 62.8(11.4) years, BMI: 32.2(6.8) kg/m<sup>2</sup>, baseline HbA1c 9.0(0.9) % [75 (10) mmol/mol]). Commencement of flash glucose monitoring was associated with an HbA1c reduction of 0.89 % (95 % CI 0.71 to 1.08) (9.8 mmol/mol (95 % CI 7.8 to 11.8)) at 3–6 months. In the one stage model, age, BMI and baseline HbA1c accounted for the substantial heterogeneity observed between studies.</div></div><div><h3>Conclusions</h3><div>Commencement of flash glucose monitoring was associated with a significant reduction in HbA1c at 3–6 months in a real-world setting in T2DM managed with insulin.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"219 ","pages":"Article 111950"},"PeriodicalIF":6.1000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes research and clinical practice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S016882272400860X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Aims

There is a growing body of evidence demonstrating the benefit of flash glucose monitoring in type 2 diabetes mellitus (T2DM). This individual patient data meta-analysis aimed to investigate the impact of commencing flash glucose monitoring on HbA1c in people living with T2DM treated with insulin in a real-world setting.

Methods

A meta-analysis of eight observational studies which assessed change in HbA1c at 3–6 months following initiating flash glucose monitoring for which Abbott Diabetes Care could provide individual patient data was performed. Studies included adults with T2DM managed with insulin and baseline HbA1c between 8.0 %–12.0 % (64–108 mmol/mol). A one-stage model was created to explore heterogeneity.

Results

A total of 803 patients were included in the analysis (mean(SD) age: 62.8(11.4) years, BMI: 32.2(6.8) kg/m², baseline HbA1c 9.0(0.9) % [75 (10) mmol/mol]). Commencement of flash glucose monitoring was associated with an HbA1c reduction of 0.89 % (95 % CI 0.71 to 1.08) (9.8 mmol/mol (95 % CI 7.8 to 11.8)) at 3–6 months. In the one stage model, age, BMI and baseline HbA1c accounted for the substantial heterogeneity observed between studies.

Conclusions

Commencement of flash glucose monitoring was associated with a significant reduction in HbA1c at 3–6 months in a real-world setting in T2DM managed with insulin.

查看原文本刊更多论文

快速血糖监测对2型糖尿病患者HbA1c的疗效：现实世界证据的个体患者数据荟萃分析

目的：越来越多的证据表明，快速血糖监测对2型糖尿病（T2DM）有益。这项个体患者数据荟萃分析旨在调查在现实世界中胰岛素治疗的T2DM患者开始快速血糖监测对HbA1c的影响方法：对8项观察性研究进行荟萃分析，评估在开始快速血糖监测3-6 个月后HbA1c的变化，雅培糖尿病护理公司可以提供个体患者数据。研究纳入胰岛素治疗的T2DM成人患者，基线HbA1c在8.0 %-12.0 %（64-108 mmol/mol）之间。我们建立了一个单阶段模型来探讨异质性。结果：共有803例患者纳入分析(平均（SD）年龄：62.8（11.4）岁，BMI: 32.2(6.8) kg/m2，基线HbA1c 9.0（0.9) % [75 (10) mmol/mol]）。在3-6个月至 个月内，开始快速血糖监测与HbA1c降低0.89 %(95 % CI 0.71至1.08)(9.8 mmol/mol（95 % CI 7.8至11.8）相关。在单阶段模型中，年龄、BMI和基线HbA1c是研究间观察到的实质性异质性的原因。结论：在胰岛素治疗的T2DM患者中，在3-6 个月时，开始快速血糖监测与HbA1c显著降低相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes research and clinical practice 医学-内分泌学与代谢

CiteScore

10.30

自引率

3.90%

发文量

862

审稿时长

32 days

期刊介绍： Diabetes Research and Clinical Practice is an international journal for health-care providers and clinically oriented researchers that publishes high-quality original research articles and expert reviews in diabetes and related areas. The role of the journal is to provide a venue for dissemination of knowledge and discussion of topics related to diabetes clinical research and patient care. Topics of focus include translational science, genetics, immunology, nutrition, psychosocial research, epidemiology, prevention, socio-economic research, complications, new treatments, technologies and therapy.